학술논문
Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.
Document Type
Article
Author
Source
Subject
*MYELODYSPLASTIC syndromes
*EOSINOPHILS
*CYTOGENETICS
*FIBRINOLYTIC agents
*ERYTHROCYTES
*
*
*
*
Language
ISSN
1042-8194
Abstract
The article presents a study which shows the clinical features and response to lenalidomide in case of myelodysplastic syndrome (MDS) with isolated del(5q) and JAK2 V617F mutation. An 85-year-old woman, diagnosed with MDS, was treated with lenalidomide was started along with antithrombotic prophylaxis was after transfusion of two red blood cells (RBC) units. The cytogenetic evaluation reveals abnormality in del(5q) and a mild eosinophil increase (4%) was detected.